Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-10-10
2011-12-27
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S131000
Reexamination Certificate
active
08084477
ABSTRACT:
The present invention provides a novel alpha-(N-sulfonamido)acetamide compound, its pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease and other conditions associated with β-amyloid peptide.
REFERENCES:
patent: 5274094 (1993-12-01), Whittaker et al.
patent: 5516783 (1996-05-01), Whittaker et al.
patent: 6153612 (2000-11-01), Ortwine et al.
patent: 6313123 (2001-11-01), Levin et al.
patent: 7144894 (2006-12-01), Gilligan
patent: 7300936 (2007-11-01), Parker et al.
patent: 7300951 (2007-11-01), Kreft et al.
patent: 2007/0197800 (2007-08-01), Chan et al.
patent: 2007/0197830 (2007-08-01), Chan et al.
patent: 2008/0085894 (2008-04-01), Parker et al.
patent: 2010/0240719 (2010-09-01), Starrett et al.
patent: 11-343279 (1999-12-01), None
patent: WO 98/03166 (1998-01-01), None
patent: WO 00/44716 (2000-08-01), None
patent: WO 00/50391 (2000-08-01), None
patent: WO 2008/112249 (2008-09-01), None
patent: WO 2009/005688 (2009-01-01), None
Chapman, P.F. et al., “Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice”, Nature Neuroscience, vol. 2, No. 3, pp. 271-276 (1999).
Dahlgren, K.N. et al., “Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability”, The Journal of Biological Chemistry, vol. 277, No. 35, pp. 32046-32053 (2002).
Golde, T.E., “Alzheimer's disease therapy: Can the amyloid cascade be halted?”, The Journal of Clinical Investigation, vol. 111, No. 1, pp. 11-18 (2003).
Götz, J. et al., “Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils”, Science, vol. 293, pp. 1491-1495 (2001).
Lewis, J. et al., “Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP”, Science, vol. 293, pp. 1487-1491 (2001).
Loane, D.J. et al., “Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury”, Nature Medicine, Advance Online Publication, pp. 1-3 (Mar. 15, 2009).
Mayer, S.C. et al., Discovery of Begacestat, a Notch-1-Sparing γ-Secretase Inhibitor for the Treatment of Alzheimer's Disease, Journal of Medicinal Chemistry, vol. 51, No. 23, pp. 7348-7351 (2008).
McLean, C.A. et al., “Soluble Pool of Aβ Amyloid as a Determinant of Severity of Neurodegeneration in Alzheimer's Disease”, Annals of Neurology, vol. 46, No. 6, pp. 860-866 (1999).
Seiffert, D. et al., “Presenilin-1 and -2 are Molecular Targets for γ-Secretase Inhibitors”, The Journal of Biological Chemistry, vol. 275, No. 44, pp. 34086-34091 (2000).
Selkoe, D.J., “Alzheimer's Disease: Genes, Proteins, and Therapy”, Physiological Reviews, vol. 81, No. 2, pp. 741-766 (2001).
Selkoe, D.J., “Cell Biology of the Amyloid β-Protein Precursor and the Mechanism of Alzheimer's Disease”, Ann. Rev. Cell Biol., vol. 10, pp. 373-403 (1994).
Siemers, E.R. et al., “Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease”, Neurology, vol. 66, pp. 602-604 (2006).
Thal, D.R. et al., “Two Types of Sporadic Cerebral Amyloid Angiopathy”, Journal of Neuropathology and Experimental Neurology, vol. 61, No. 3, pp. 282-293 (2002).
Walsh, D.M. et al, “Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo”, Nature, vol. 416, pp. 535-539 (2002).
Watkins, T.A. et al., “Distinct Stages of Myelination Regulated by γ-Secretase and Astrocytes in a Rapidly Myelinating CNS Coculture System”, Neuron, vol. 60, pp. 555-569 (2008).
Wolfe, M.S., “Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential”, Journal of Medicinal Chemistry, vol. 44, No. 13, pp. 2039-2060 (2001).
2008 CSHL Meeting on Neurodegenerative Diseases, Oral Presentation, Dec. 5, 2008.
2009 BMS URG Symposium, Oral Presentation, May 1, 2009.
237th National American Chemical Society Meeting, Salt Lake City, Utah, Oral Presentation, Mar. 22, 2009.
Gordon Research Conference, Newport, RI, Oral Presentation, Jun. 30, 2009.
International Conference on Alzheimer's Disease, Chicago, IL, Abstract, Jul. 26, 2008.
International Conference on Alzheimer's Disease, Chicago, IL, Oral Presentation, Jul. 30, 2008.
Gillman Kevin W.
Olson Richard E.
Starrett, Jr. John E.
Algieri Aldo A.
Bristol--Myers Squibb Company
Mingo Pamela A.
Saeed Kamal
LandOfFree
Alpha-(N-sulfonamido)acetamide compound as an inhibitor of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-(N-sulfonamido)acetamide compound as an inhibitor of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-(N-sulfonamido)acetamide compound as an inhibitor of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4306297